KR101580008B1 - A composition for the treatment or prevention of pneumonia comprising Hexanedioic acid - Google Patents

Abstract

In the present invention, hexane diol acid (Hexanedioic acid) has been shown to have antimicrobial activity or antimicrobial effect against pneumococcus by inducing the growth inhibition effect of pneumococcal bacilli, and as a composition for treating, improving or preventing pneumonia using the same Respectively.
The present invention relates to a pharmaceutical composition for the treatment or prevention of pneumonia comprising hexane diol acid (Hexanedioic acid) as an active ingredient, a health food composition for prevention or improvement, and a feed composition for prevention or improvement.
The pharmaceutical compositions, health food compositions and feed compositions according to the present invention can be effectively used as antimicrobial agents for treating, ameliorating or preventing pneumonia by inhibiting growth and proliferation of pneumococcal bacilli and inducing growth inhibition.

Description

TECHNICAL FIELD The present invention relates to a composition for treating or preventing pneumonia comprising hexanediol acid,

The present invention relates to a pharmaceutical composition for the treatment or prevention of pneumonia comprising hexane diol acid (Hexanedioic acid) as an active ingredient, a health food composition for prevention or improvement, and a feed composition for prevention or improvement.

Hundreds of years ago, 3 out of 10 children died before they were 1, and about half died before 10 years old. The reason was due to illnesses such as smallpox, measles, malaria, cholera, dysentery, pneumonia, and sepsis. Findings of penicillin during the inhibition and treatment of these diseases have become a turning point that has led to major changes in antibiotic-induced inhibition of pathogens, improvement of health health and prolongation of life by inhibition of disease.

However, direct or indirect damages caused by pathogenic microorganisms and resistant bacteria still cause many problems and diseases in economy, environment, medicine and health. The use of chemical pesticides in agriculture for agricultural products and the use of antibiotics in the aquaculture industry, the harmfulness and environmental pollution of the human body, the antibiotic resistance due to abuse of a wide range of antibiotics The emergence of strains has caused many problems in society as a whole. In particular, recently, microorganisms showing extensive resistance to antibiotics have been discovered and the problem of resistance to antibiotics has become serious, and the research and development and dissemination of new antibiotics are urgently required. In addition, antibiotics generally play a very important role not only in humans but also in animal husbandry. In order to increase the number of rearing per unit area and to improve the productivity, the prevention and treatment of disease was an important factor of the successful axis and fisheries industry in accordance with the development of axis and fisheries including past agriculture. Therefore, various antibiotics and growth promoters have been developed and distributed and applied in the field. This increase in the amount of antibiotics caused resistance and contamination to axes and aquatic products. Furthermore, through the bioconcentration phenomenon, not only does it induce drug resistance to humans consuming and consuming axes and aquatic products, The situation reached.

Most of the currently used antibiotics are produced through chemical synthesis, and thus exhibit many limitations such as resistance, contamination and side effects as described above. Therefore, recently, researches for separating and developing new antimicrobial substances from natural products including animals, plants, microorganisms and various medicinal plants and medicinal plants are being actively carried out, and development of a human-friendly substance capable of replacing antibiotic functions is important It is becoming a challenge. However, research and development of these new antimicrobial substances is not easy. In order to develop a new antimicrobial substance, it is necessary to consider that the antimicrobial spectrum is broad and antimicrobial effect is exerted on existing resistant strains, and that even long-term administration is safe without side effects.

Under these circumstances, the present inventor has made intensive efforts to develop a new antimicrobial substance. As a result, the present inventors have completed the present invention by confirming that "Hexanedioic acid" known as a chemical substance has a high growth inhibitory action or antimicrobial activity in a pneumococcal strain.

It is an object of the present invention to provide a pharmaceutical composition for the treatment or prevention of pneumonia caused by Klebsiella pneumoniae containing hexanedioic acid as an active ingredient.

It is another object of the present invention to provide a health food composition for preventing or ameliorating pneumonia comprising hexanedioic acid as an active ingredient.

It is another object of the present invention to provide a feed composition for preventing or improving pneumonia comprising hexane diol acid (Hexanedioic acid) as an active ingredient.

In order to achieve the above object, the present invention provides a pharmaceutical composition for the treatment or prevention of pneumonia caused by pneumoniae bacilli containing hexanedioic acid as an active ingredient.

The term "hexanedioic acid" used in the present invention is also called "adipic acid" or "hexane-1,6-dioic acid" and is white crystals having the chemical structure C ₆ H ₁₀ O ₄ and the molar mass ) Is 146.14 g / mole. The antimicrobial activity of Hexanedioic acid was measured by dissolving Hexanedioic acid in distilled water. In one embodiment of the present invention, the Hexanedioic acid inhibited the growth and proliferation of pneumoniae and inhibited the survival of pneumococci, thereby confirming antimicrobial activity against pneumococci (FIGS. 1 and 2).

The term " pneumonia " as used in the present invention means inflammation of the lungs caused by infection caused by microorganisms such as bacteria, viruses and fungi, and respiration due to obstruction of breathing function due to coughing, It is a disease in which systemic diseases occur throughout the whole body such as lung symptoms, obstruction, vomiting, diarrhea and other digestive symptoms and disorders such as headache, fatigue, muscle pain, and arthralgia. The pneumonia which can be prevented or treated by the pharmaceutical composition of the present invention is not limited thereto, but may be preferably bacterial pneumonia, more preferably pneumonia caused by Klebsiella pneumoniae.

delete

delete

delete

delete

As used herein, the term " Klebsiella pneumoniae " is gram-negative staphylococci and is a pathogenic microorganism having no motility, no flagella, no sporangia, and a caudate. It is a common allergic bacterial strain that develops well in agar. It is found in the intestines and oral cavity of humans. It is a cause of acute pneumonia. It is separated from bronchopneumonia and urinary tract infections. In addition, pneumococci commonly cause genitourinary tract infections, community pneumonia, liver abscess, and endogenous endophthalmitis.

delete

delete

delete

delete

delete

delete

delete

In the present invention, the therapeutic or prophylactic effect of pneumonia in the pharmaceutical composition is attained by inhibiting the growth and proliferation of Klebsiella pneumoniae and inhibiting its survival, thereby having an inhibitory effect on growth or antibacterial activity against pneumonia bacillus have. In one embodiment of the present invention, Hexanedioic acid has the antimicrobial activity against pneumococci by inducing the growth and proliferation inhibition or growth inhibition action of the pneumococcal bacillus, thereby achieving the treatment or prevention of pneumonia (Figs. 1 to 2).

As used herein, the term " antibacterial " as used herein means an effect against bacteria, more specifically, a bacterial and fungal growth inhibition, proliferative growth inhibition or growth inhibitory action by a drug, a physiologically active substance or a known chemical substance. For the purpose of inhibiting the growth and proliferation of the bacterium of the pneumonia or inhibiting growth thereof. In one embodiment of the present invention, it was confirmed through the TB assay that the hexanedioic acid caused growth inhibition, proliferation inhibition or survival inhibition of pneumococcal bacilli and antimicrobial activity against pneumococci (FIGS. 1 and 2).

The hexanedioic acid of the present invention is not limited thereto, but may be a synthetic material obtained by chemical synthesis or a substance derived from an animal, a plant and an insect. The hexanedioic acid can be obtained by an extraction method or a separation and purification method derived from common synthetic methods, animals, plants and insects known in the art. The extraction method of the extract is not limited thereto, but organic solvent extraction, hot water extraction, hot water extraction, cold extraction, reflux cooling extraction or ultrasonic extraction may be used.

In the present invention, the solvent used for extracting, extracting, or preparing the hexanedioic acid may be water or organic solvent commonly used in the art. Examples of the solvent include water, hexane, chloroform, Ethanol, methanol, butanol, acetate, acetone, acetonitrile, benzene, dichloromethane, or a mixed solvent thereof may be used as the solvent.

&Quot; Prevention " used in the present invention means all the actions of inhibiting or delaying the onset of the disease upon administration of the composition, and " treatment " means any action that alleviates or alleviates symptoms of the disease upon administration of the composition do.

The pharmaceutical composition of the present invention may comprise a pharmaceutically acceptable carrier. Compositions comprising a pharmaceutically acceptable carrier can be of various oral or parenteral formulations. In the case of formulation, it can be prepared using diluents or excipients such as fillers, extenders, binders, humectants, disintegrants, surfactants and the like which are usually used. Solid formulations for oral administration may include tablet pills, powders, granules, capsules, and the like, which may contain one or more excipients, such as starch, calcium carbonate, sucrose, or lactose lactose, gelatin, and the like. In addition to simple excipients, lubricants such as magnesium stearate, talc, and the like may also be used. Liquid preparations for oral administration include suspensions, solutions, emulsions, syrups and the like. Various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included in addition to water and liquid paraffin, which are simple diluents commonly used. have. Formulations for parenteral administration may include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of the non-aqueous solvent and the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate. Examples of the suppository base include witepsol, macrogol, tween 61, cacao paper, laurin, glycerogelatin and the like.

The pharmaceutical composition of the present invention may also be in the form of tablets, pills, powders, granules, capsules, suspensions, solutions, emulsions, syrups, sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, Or a pharmaceutically acceptable salt thereof.

The dosage form of the pharmaceutical composition of the present invention is not particularly limited and may be varied depending on the degree of absorption, body weight, age, sex, health condition, diet, administration time, administration method, excretion rate, have. The pharmaceutical composition of the present invention is prepared in consideration of an effective dose range, and the unit dosage formulations thus formulated are classified according to the judgment of the expert who monitors or observes the administration of the drug, if necessary, Or may be administered several times at a predetermined time interval.

In another aspect, the present invention provides a health food composition for preventing or ameliorating pneumonia comprising hexane diol acid (Hexanedioic acid) as an active ingredient. The health food composition may be achieved by suppressing the growth and proliferation of pneumococcal bacilli and inhibiting the viability of the poultry bacillus, thereby having a growth inhibitory effect or an antimicrobial activity against pneumonia bacilli, as described above.

When the composition of the present invention is used as an additive for a health food, the composition may be added as it is or may be used together with other health food or its components, and may be suitably used according to a conventional method. The amount of the active ingredient to be mixed may be appropriately determined depending on the purpose of use, and the amount of the composition of the present invention is not particularly limited.

The types of health foods of the present invention include functional foods, food additives, and the like, and there is no particular limitation. Examples of the health food to which the composition can be added include dairy products including meat, sausage, bread, chocolate, candy, snack, confectionery, pizza, ramen, other noodles, gums, ice cream, soups, drinks, tea, , Alcoholic beverages, and vitamin complexes, and may include foods used as feed for animals, which may include all health foods in a conventional sense. In addition, when the health functional food composition of the present invention is used in the form of a drink, it may contain various sweetening agents, flavoring agents, or natural carbohydrates as additional components such as ordinary beverages. In addition to the above, the health functional food composition of the present invention may contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloid thickening agents, pH adjusting agents, stabilizers, , Alcohols, carbonating agents used in carbonated drinks, and the like. It may also contain flesh for the production of natural fruit juices, fruit juice drinks and vegetable drinks.

In another aspect, the present invention provides a feed composition for preventing or improving pneumonia comprising hexane diol acid (Hexanedioic acid) as an active ingredient. The feed composition may be achieved by suppressing the growth and proliferation of pneumococcal bacilli and inhibiting the viability of the poultry bacillus, thereby having an inhibitory effect on the growth of pneumococcus or an antimicrobial activity, as described above.

When the composition of the present invention is used as a feed additive, the composition may be added as it is or may be mixed with other feed ingredients and used appropriately according to a conventional method. The amount of the active ingredient to be mixed may be appropriately determined depending on the purpose of use, and the amount of the composition of the present invention is not particularly limited.

There is no particular limitation on the kind of feed of the present invention. The composition may be supplemented with various kinds of auxiliaries such as amino acids, inorganic salts, vitamins, antioxidants, microbial preparations and the like and crushed or crushed wheat, vegetable protein feeds such as barley and corn, animal protein feeds such as blood, May be used in combination with nutritional supplements, growth promoters, digestion-absorption promoters, and disease prevention agents in addition to the main components such as fat and vegetable fats. The dosage form, method and formulation of the feed can vary and are as described above.

The feed composition of the present invention can be applied to a large number of animal diets, i.e. feeds, including mammals, poultry, fish and crustaceans. It can be used for zoo animals such as elephants, camels, giraffes and monkeys, pets such as dogs and cats, including chickens, ducks, geese, Pigeons, and other commercially available fish and crustaceans such as carp, carp, trout, mullet, and shrimp.

The pharmaceutical composition, health food composition and feed composition according to the present invention can be used for the treatment, improvement or prevention of pneumonia by inducing the growth and proliferation inhibition or growth inhibition action of pneumococcal bacillus and having antimicrobial activity against pneumonia bacillus Can be provided.

FIG. 1 is a graph showing the results of measurement of antimicrobial activity of Hexanedioic acid by inhibiting the growth and proliferation inhibition or survival inhibition of pneumococcal bacilli by applying hexanedioic acid to the TB assay. The "+" indicates the growth-inhibiting action or the antibacterial activity of the test substance against pneumococcal bacteria.
FIG. 2 is a graph showing the antimicrobial activity of Hexanedioic acid according to the concentration of Hexanedioic acid applied to the TB assay to inhibit the growth and proliferation inhibition or survival inhibition of pneumococcal bacilli.

Hereinafter, the present invention will be described in more detail with reference to examples. However, these examples are for illustrative purposes only, and the scope of the present invention is not limited to these examples.

Example 1: Measurement of antimicrobial activity by TB assay

To determine the antimicrobial activity or antimicrobial activity of Hexanedioic acid against pneumococcal bacilli, Hexanedioic acid and distilled water were used to prepare Hexanedioic acid solution at different concentrations and then applied to the TB assay to measure the antimicrobial activity of the test substance against B. pneumoniae.

First, Hexanedioic acid solution was used to measure growth inhibition and antimicrobial activity of P. pneumoniae.

The TB assay procedure is as follows. First, LB (Luria-Bertani broth) liquid medium was placed in a glass flask or bottle, then the strain was inoculated in a LB (Luria-Bertani broth) liquid medium and cultured in a 37 ° C. incubator for 24 hours. Thereafter, 150 μl of the strain was added to each well of a 96-well plate, and the test solution was administered at a concentration. After 12 hours, the absorbance of each strain was measured, and a normal culture strain And the percent of antimicrobial activity was calculated.

As a result, it was confirmed through the TB assay experiment that the test substance Hexanedioic acid has a high concentration-dependent high growth inhibitory activity or antimicrobial activity against pneumococci (Figs. 1 and 2). These results indicate that hexanedioic acid can be used as an antimicrobial composition against pneumonia.

Claims (4)

A pharmaceutical composition for treating or preventing pneumonia caused by Klebsiella pneumoniae containing hexanedioic acid as an active ingredient.
The pharmaceutical composition according to claim 1, wherein the composition induces growth inhibition of Klebsiella pneumoniae.
A health food composition for preventing or ameliorating pneumonia comprising hexane diol acid (Hexanedioic acid) as an active ingredient.
A feed composition for preventing or improving pneumonia comprising hexanedioic acid as an active ingredient.

Images